Ocugen Appoints Rita Johnson-Greene as New Chief Financial Officer

summarizeSummary

Ocugen, Inc. has appointed Rita Johnson-Greene as its new Chief Financial Officer, effective February 9, 2026, with a compensation package including a $440,000 base salary, a $90,000 sign-on bonus, and significant equity awards.

check_boxKey Events

• New Chief Financial Officer Appointed

  Rita Johnson-Greene has been appointed as Chief Financial Officer, effective February 9, 2026, and will become Principal Financial Officer after the 2025 10-K filing.

• Experienced Financial Leader Joins

  Ms. Johnson-Greene previously served as COO of Alliance for Regenerative Medicine and held leadership roles at bluebird bio, Spark Therapeutics, and AstraZeneca.

• Compensation Package Detailed

  Her compensation includes an annual base salary of $440,000, a target annual bonus of up to 45% of base salary, and a one-time sign-on bonus of $90,000.

• Significant Equity Awards Granted

  She received an option to purchase 750,000 shares and 500,000 restricted stock units (RSUs), both vesting over three years.

auto_awesomeAnalysis

Ocugen, Inc. announced the appointment of Rita Johnson-Greene as its new Chief Financial Officer, a critical leadership role for a life sciences company with ongoing clinical trials and recent capital raises. Ms. Johnson-Greene brings extensive experience from previous roles at Alliance for Regenerative Medicine, bluebird bio, Spark Therapeutics, and AstraZeneca, which is valuable for guiding the company's financial strategy. The compensation package, including a substantial equity grant, is designed to attract and retain experienced talent, signaling the company's commitment to strengthening its executive team following recent financing activities.